ARDM

  0%
Previous Close
Open
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0
Stock charts supplied by TradingView

NewsSee all news

  1. Aradigm Announces Withdrawal of European Marketing Authorization Application (MAA) for Linhaliq

    Aradigm Corporation (OTCQB:ARDMQ) ("Aradigm" or the "Company") today announced that following a recent Oral Explanation, it has withdrawn its Marketing Authorization Application (MAA) for Linhaliq as a treatment for

  2. Aradigm Receives Feedback Following an Oral Explanation With the European Medicines Agency

    Aradigm Corporation (OTCQB:ARDM) ("Aradigm" or the "Company") today announced that following a recent Oral Explanation, it has received feedback that a negative opinion is likely to be received in November 2019 from the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval granted July 16, 2009.
Sumavel
Migraine
Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).

Latest News

  1. Aradigm Announces Withdrawal of European Marketing Authorization Application (MAA) for Linhaliq

    Aradigm Corporation (OTCQB:ARDMQ) ("Aradigm" or the "Company") today announced that following a recent Oral Explanation, it has withdrawn its Marketing Authorization Application (MAA) for Linhaliq as a treatment for

  2. Aradigm Receives Feedback Following an Oral Explanation With the European Medicines Agency

    Aradigm Corporation (OTCQB:ARDM) ("Aradigm" or the "Company") today announced that following a recent Oral Explanation, it has received feedback that a negative opinion is likely to be received in November 2019 from the